Using CRISPR and other tools, scientists are modifying DNA methylation, histone marks, and other modifiers of gene expression to understand how they affect health and disease.
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.